Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe most common side effects of tirzepatide are gastrointestinal: nausea, diarrhoea, vomiting, constipation and indigestion appear in a significant proportion of people who take it, particularly in the early weeks or after a dose increase. They are usually mild to moderate and tend to settle as the body adjusts. Tirzepatide is a prescription-only medicine; a clinical assessment by a qualified prescriber determines whether it is suitable for you personally. Our prescribers at nume discuss side effects and suitability as part of every consultation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Nausea is the one patients mention most. It tends to arrive within the first day or two after an injection and, for most people, fades noticeably within a week. Diarrhoea and constipation can alternate, which catches some people off guard; loose stools are more common early on, while constipation sometimes becomes the bigger issue once the body settles. Indigestion, burping and a general feeling of fullness (even after small meals) are also part of the picture that the NHS tirzepatide medicines page describes as typical GI effects.
Fatigue and headache appear in a smaller but still meaningful proportion of people, usually in the first week of a new dose. Injection-site reactions (mild redness, itching or a small lump at the site) are generally harmless and resolve quickly with proper site rotation between the abdomen, thigh and upper arm.
The practical detail that makes a real difference: timing your injection so the peak-nausea window doesn't land in the middle of a busy day. Many people find the evening works well. Eating a light, low-fat meal before the injection and keeping a glass of water nearby helps too. For a fuller picture of how often these effects occur across the clinical programme, the frequency data behind Mounjaro side effects breaks this down in more detail.
Most side effects from tirzepatide are manageable at home, but several warrant prompt medical attention. The most important signal is severe, persistent stomach pain that reaches into your back, with or without vomiting — this can indicate acute pancreatitis, a known but infrequent risk of GLP-1 class medicines. In January 2026 the MHRA issued a formal Drug Safety Update specifically flagging this risk for GLP-1 receptor agonists; you can read it and report any concern through the Yellow Card portal.
Other situations that need the same-day attention of a GP or urgent care: signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, a rapid or pounding heartbeat), symptoms of severe dehydration after prolonged vomiting or diarrhoea (dizziness, very dark urine, inability to keep fluids down), or significant gallbladder pain, sharp pain in the upper right abdomen, particularly after eating.
If you are on tirzepatide through nume and something doesn't feel right, our aftercare team is available seven days a week. That said, anything acute (chest pain, breathing difficulty, collapse) means 999, not a message to a pharmacy. Our broader side-effect guide for tirzepatide covers the full list, including rarer effects worth knowing about before you start.
Understanding this is the core decision most people are actually working through: not whether side effects exist, but whether the likely experience is something they can manage given their circumstances. The clinical trial programme (SURMOUNT-1, involving more than 2,500 participants over 72 weeks) showed that the majority of people who experienced GI effects found them transient rather than treatment-ending. Discontinuation rates due to side effects were lower than many people expect when they read the list cold.
Tirzepatide is a dual GIP and GLP-1 receptor agonist, and its mechanism (slowing gastric emptying and reducing appetite signals) is the same reason nausea occurs in the first place. The graduated dosing schedule, starting at 2.5mg before any therapeutic dose, exists largely to give the gut time to adapt. Jumping straight to a maintenance dose would produce a very different side-effect experience.
Some people find side effects are a deciding factor, and our page covering the common side effects of Mounjaro gives a clear sense of what most patients actually report week to week. For others, the broader context (including cost, the injection format, and the clinical evidence on results) shapes the decision more. What matters is making that call with accurate information rather than the worst-case headlines, and our tirzepatide side effects guide is a good starting point if you want to read through everything before your consultation. Our prescribers work through the full picture with you during the consultation; there is no pressure to proceed if it isn't right for you. You can explore the treatment options available through our free consultation at any point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.